Rafael Holdings, Inc.

RFL

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001713863

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $114.1M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	late filer, thin data, degenerate inputs not computable: dilution, distress, fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Oct 29, 2025 362 days before the rescan; latest periodic filing 10-Q received Jun 11, 2026
Last close	$1.29 2026-10-23; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Oct 29, 2025

"Rafael", "we" or the "Company") is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol® Cyclo?, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder. We also hold: (i) a majority equity interest in LipoMedix Pharmaceuticals Ltd. ("LipoMedix"), a clinical stage pharmaceutical company; (ii) Barer Institute Inc.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 38.3						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2024-07-31; latest annual assets end 2025-07-31						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(11.0%)	(6.6%)	38.3	807	2025-07-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 2					
Solvency, sleeve percentile 51.9					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-04-30					
Altman Z double-prime	0.54	(0.33)	35.4	752	2025-07-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	(44.31x)	(4.51x)	82.5	81	2025-07-31
Current ratio	4.89x	2.94x	37.7	834	2025-07-31
Growth and financing, sleeve percentile 75.3					
Revenue growth, three-year compound	(58.2%)	10.1%	96.4	413	2025-07-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 6					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(1.2%)	2.1%	54.2	700	2025-07-31
Net share issuance, one year	not computable	2.5%			
two annual share counts are required; found 0					

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	89.0%	7.7%	86
Distance from 52-week high	(65.3%)	(31.4%)	17
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.42	(0.14)	86

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-07-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$30.5M
Operating cash flow, four quarters	-$32.0M
Months of runway	11.4
Days since last periodic filing	137 (10-Q received Jun 11, 2026)
Median daily dollar volume, 63 sessions	$170,874

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$637,000	2024-07-31	2025-10-29	10-K	25-103549
2	cost of revenue	us-gaap:CostOfRevenue	$154,000	2024-07-31	2024-12-20	10-K/A	24-110663
3	assets	us-gaap:Assets	$96.8M	2024-07-31	2025-10-29	10-K	25-103549
4	net income	us-gaap:NetIncomeLoss	-$30.5M	2025-07-31	2025-10-29	10-K	25-103549
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.9M	2025-07-31	2025-10-29	10-K	25-103549
6	assets	us-gaap:Assets	$114.1M	2025-07-31	2025-10-29	10-K	25-103549
7	current assets	us-gaap:AssetsCurrent	$56.7M	2025-07-31	2025-10-29	10-K	25-103549
8	current liabilities	us-gaap:LiabilitiesCurrent	$11.6M	2025-07-31	2025-10-29	10-K	25-103549
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$232.3M	2025-07-31	2025-10-29	10-K	25-103549
10	operating income	us-gaap:OperatingIncomeLoss	-$29.2M	2025-07-31	2025-10-29	10-K	25-103549
11	book equity	us-gaap:StockholdersEquity	$94.4M	2025-07-31	2025-10-29	10-K	25-103549
12	liabilities	us-gaap:Liabilities	$15.7M	2025-07-31	2025-10-29	10-K	25-103549
13	interest expense	us-gaap:InterestExpense	$658,000	2025-07-31	2025-10-29	10-K	25-103549
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$30,000	2025-07-31	2025-10-29	10-K	25-103549
15	revenue	us-gaap:Revenues	$279,000	2023-07-31	2024-12-20	10-K/A	24-110663
16	revenue	us-gaap:Revenues	$410,000	2022-07-31	2023-10-30	10-K	23-081589
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$206,000	2021-07-31	2021-10-18	10-K	21-053306
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$70,000	2021-07-31	2022-10-31	10-K	22-067711
19	operating income	us-gaap:OperatingIncomeLoss	-$28.2M	2021-07-31	2022-10-31	10-K	22-067711
20	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$23.4M	2021-07-31	2022-10-31	10-K	22-067711
21	income tax	us-gaap:IncomeTaxExpenseBenefit	$18,000	2021-07-31	2022-10-31	10-K	22-067711
22	current assets	us-gaap:AssetsCurrent	$14.8M	2021-07-31	2022-10-31	10-K	22-067711
23	current liabilities	us-gaap:LiabilitiesCurrent	$17.3M	2021-07-31	2022-10-31	10-K	22-067711
24	current assets	us-gaap:AssetsCurrent	$9.8M	2020-07-31	2021-10-18	10-K	21-053306
25	current liabilities	us-gaap:LiabilitiesCurrent	$5.7M	2020-07-31	2021-10-18	10-K	21-053306
26	assets	us-gaap:Assets	$98.8M	2023-07-31	2024-12-20	10-K/A	24-110663
27	assets	us-gaap:Assets	$118.3M	2022-07-31	2023-10-30	10-K	23-081589

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.